Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tolebrutinib,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : old Sano
Deal Size : Undisclosed
Deal Type : Collaboration
Koneksa Broadens Multi-Year CNS Research Collaboration with Sanofi
Details : Koneksa's work with Sanofi will support the investigation of tolebrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, which is an oral, brain-penetrant, selective small molecule currently in Phase III trial.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 11, 2021
Lead Product(s) : Tolebrutinib,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : old Sano
Deal Size : Undisclosed
Deal Type : Collaboration